News

The London-based orthopedic giant is set to debut the recently acquired CartiHeal Agili-C cartilage repair implant. CartiHeal was initially slated for acquisition by Bioventus last summer, but the deal fell through. Subsequently, Smith+Nephew executed a $180 million buyout in November 2023, with the possibility of an additional $150 million.

Alongside the CartiHeal technology, the company also plans to unveil the Regeneten bioinductive implant at the AAOS Annual Meeting in San Francisco this week. Smith+Nephew asserts that these technologies have the potential to revolutionize soft tissue repair treatments compared to the existing standard of care.

The Agili-C implant from CartiHeal offers an accessible solution for osteochondral lesions without the need for donor tissue. It caters to a diverse patient population, including cases of trauma and osteoarthritis, as well as standard cartilage repair. This system, already available in the U.S., obtained FDA premarket approval in 2022.

Regeneten, another innovation by Smith+Nephew, provides a patient-centric treatment that supports the body’s natural healing process. This collagen-based implant has the potential to alter the course of tear progression, facilitate a return to normal activity, and reduce re-tears in comparison to conventional surgery. Having demonstrated success in treating rotator cuff tears, the company anticipates similar potential benefits for Achilles repair.

“As a leader in sports medicine, we are committed to bringing emerging technologies that address unmet clinical needs to our customers and their patients,” said Scott Schaffner, president of Sports Medicine, Smith+Nephew. “Both Regeneten and CartiHeal Agili-C implants have the opportunity to set new benchmarks for standard of care across multiple joint repair indications and deliver better patient outcomes.”

© Smith & Nephew Plc.